Zhehai Wang

机构：Shandong Tumor Hospital, Ministry of Education, Tumor Hospital of Guangxi Medical University, Shandong First Medical University · ORCID：0000-0002-5021-8580

发表论文 27 篇 · 总被引 221 次 · h-index 7

代表论文

• EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer (2014 · Drug Design Development and Therapy · 被引 70)
• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial (2022 · Journal for ImmunoTherapy of Cancer · 被引 23)
• A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study (2024 · Cancer · 被引 17)
• HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer (2023 · Clinical Cancer Research · 被引 14)
• Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report (2024 · Journal of Thoracic Oncology · 被引 7)